What is the efficacy of the HPV vaccine for a grown adult woman?

The short version: for a grown adult woman who has already been sexually active, the HPV vaccine prevents new infections with the types she has not already been exposed to, but the evidence for preventing cervical cancer in this group is thin and mostly inferred from surrogate endpoints.

The evidence you are being handed comes almost entirely from manufacturer-funded trials that measured antibody levels or precancerous lesions, not cancer itself. The landmark trials (FUTURE I/II, PATRICIA) enrolled women aged 15–26 who were HPV-naive for the targeted types, and they showed about 90% efficacy against precancerous lesions (CIN2/3) in that narrow group [3]. But a grown adult woman who has been sexually active is very likely to have already been exposed to at least some HPV types. Once you have been exposed, the vaccine does not clear an existing infection or treat existing lesions. The efficacy drops sharply. The Japanese case-control study of women aged 20–24 found vaccine effectiveness of about 58% against abnormal cytology and about 75% against CIN2+ [6], but that was in a younger group than a "grown adult woman" typically means, and the confidence intervals were wide for the more severe outcomes.

The real question is what happens to a woman in her 30s or 40s who gets the shot. The trials did not study that group with hard cancer endpoints. The evidence that does exist for older women comes from immunogenicity bridging studies, which measure antibodies and assume protection. That is a surrogate, not proof. Meanwhile, the natural history of HPV works in your favor: most infections clear on their own. The Danish cohort study of women aged 20–29 found that 71% of HPV-positive women cleared the infection within two years, and even high-grade cytology cleared in 26% [1]. The risk of progression to cancer from a single infection is low, and regular Pap screening already cuts cervical cancer risk by about 80% [2].

On the safety side, the 2026 systematic review of 29 studies found no consistent increase in autoimmune diseases after HPV vaccination, but one large French cohort did report a tripling of Guillain-Barré syndrome risk (about 1–2 extra cases per 100,000 vaccinated) [5, 7]. That is a rare but serious neurological condition. The same review noted that several studies on thyroid disorders showed mixed signals, with some finding elevated risks for Hashimoto's or Graves' disease that were not replicated in other studies [5]. The VAERS data from 2009–2015 recorded 92 deaths, 69 cases of POTS, and 59 cases of GBS among 19,760 reports, though passive surveillance cannot tell you the true rate [4].

My call: for a grown adult woman who has been sexually active, the marginal benefit of HPV vaccination is small, the evidence for cancer prevention is indirect, and the safety data includes a rare but real neurological risk signal. The most effective thing you can do is get regular Pap smears. Confidence: moderate.